Zhang et al. (2024) reported in a meta-analysis that SGLT2 inhibitors did not reduce the risk of AF occurrence, irrespective of follow-up duration, drug type or dose, or the patient population. The gene discussed is SLC5A2; the disease is atrial fibrillation.